SciSparc Ltd. SPRC

SPRC Company Overview

SciSparc Ltd. is an Israel-based clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for disorders involving the central nervous system and other unmet medical needs. The company operates within the biotechnology and specialty pharmaceutical industries, with research centered on combinations of cannabinoids and other pharmaceutical compounds intended to improve efficacy or reduce side effects associated with conventional therapies. SciSparc’s primary value drivers are its proprietary drug-development programs, intellectual property portfolio, and clinical and preclinical research collaborations.

The company’s principal development programs have included therapies targeting Tourette syndrome, autism spectrum disorder and status epilepticus, as well as technologies involving cannabinoid-based formulations. SciSparc has also pursued development initiatives involving psychedelic-related technologies and pharmaceutical combinations through affiliated entities and investments. Originally established as Therapix Biosciences Ltd., the company later rebranded to SciSparc Ltd. as part of a broader strategic repositioning focused on cannabinoid pharmaceutical development and diversified neuropsychiatric therapeutics.